167 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
PF Pinnacle Foods, Inc. $67.54 $8.05B N/A
Article Searches
Provident Financial Services Inc (PFS) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/25/provident-financial-services-inc-pfs-q3-2019-earni.aspx?source=iedfolrf0000001 Oct 25, 2019 - PFS earnings call for the period ending September 30, 2019.
Provident Financial Services, Inc. (PFS) CEO Chris Martin on Q2 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4299274-provident-financial-services-inc-pfs-ceo-chris-martin-q2-2019-results-earnings-call?source=feed_sector_financial Oct 25, 2019 - Provident Financial Services, Inc. (NYSE:PFS) Q2 2019 Earnings Conference Call October 25, 2019 10:00 AM ET Company Participants Len Gleeson - Investor Relations John Kuntz - Corporate Secretary Chris
Provident Financial (PFS) Q3 Earnings and Revenues Beat Estimates http://www.zacks.com/stock/news/583910/provident-financial-pfs-q3-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-583910 Oct 25, 2019 - Provident Financial (PFS) delivered earnings and revenue surprises of 8.89% and 1.30%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study http://www.zacks.com/stock/news/542861/glaxos-zejula-betters-pfs-in-first-line-ovarian-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542861 Sep 30, 2019 - Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study http://www.zacks.com/stock/news/542841/astrazeneca-mercks-lynparza-improves-pfs-in-frontline-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-542841 Sep 30, 2019 - AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study http://www.zacks.com/stock/news/520871/amgens-kyprolis-combo-improves-pfs-in-multiple-myeloma-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-520871 Sep 16, 2019 - Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
Graphite One secures $4.8M for Alaskan project PFS https://seekingalpha.com/news/3498296-graphite-one-secures-4_8m-alaskan-project-pfs?source=feed_news_all Sep 10, 2019 - Graphite One (OTCQB:GPHOF +7.8%) secured $4.8M to fund a pre-feasibility study for its Graphite Creek project in Alaska.Taiga Mining, a controlling shareholder in Graphite One, is providing the loan a
Bristol-Myers' Opdivo fails to achieve PFS endpoint in late-stage brain cancer study https://seekingalpha.com/news/3497239-bristol-myers-opdivo-fails-achieve-pfs-endpoint-late-stage-brain-cancer-study?source=feed_news_all Sep 05, 2019 -
Buy And Build: The Private Equity Strategy Behind The New Class Pf 3PL Majors http://feeds.benzinga.com/~r/benzinga/~3/2hPEqVvcOw0/buy-and-build-the-private-equity-strategy-behind-the-new-class-pf-3pl-majors Jun 03, 2019 -

To gain insight into the shifting landscape of freight brokerage, sometimes it's best to follow the money, not the shiny new technology.

read more

Provident Financial Services' (PFS) CEO Chris Martin on Q1 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4257169-provident-financial-services-pfs-ceo-chris-martin-q1-2019-results-earnings-call-transcript?source=feed_sector_financial Apr 26, 2019 - Provident Financial Services, Inc. (NYSE:PFS) Q1 2019 Earnings Conference Call April 26, 2019 10:00 AM ET Company Participants Len Gleason – Senior Vice President and Investor Relations Officer Chris

Pages: 123456...17

Page 1>